RxDoctor Payments Data

Matthew Pierce, MD

Urology · New Bern, NCNPI 1508209305

Payments from drug & device makers

$5,352in general payments, 2019–2025

Across 123 payments — averaging $43.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Procept Biorobotics Corporation$852
  • Neotract Inc.$435
  • Dendreon Pharmaceuticals LLC$375
  • Sumitomo Pharma America, Inc.$273
  • Boston Scientific$264
  • plus $2K from 21 others

What the payments were for

  • Grants$120%
  • Travel & lodging$1,91436%
  • Food & beverage$3,42664%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,352 in reported general payments places this provider in the 65th percentile of 434 urology providers in North Carolina.

See all urology providers in North Carolina

Medicare billing

Part B allowed, 2024
$307,188
Medicare patients
884
Services billed
10,836

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron124$103,605
GemtesaVibegron133$81,798
PremarinEstrogens, Conjugated14$7,812
Tamsulosin Hcl399$4,899
Estradiol31$4,475
Solifenacin Succinate113$4,447
Finasteride237$2,845
Testosterone12$2,144
Oxybutynin Chloride ErOxybutynin Chloride102$1,637
Potassium Citrate ErPotassium Citrate23$1,215
Tolterodine Tartrate ErTolterodine Tartrate12$1,030
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst94$1,027
Methenamine Hippurate12$918
Desmopressin Acetate19$877
Cephalexin38$390

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$111$103,605124 claims
Sumitomo Pharma America, Inc.Gemtesa$273$81,798133 claims
PfizerPremarin$102$7,81214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 434 urology providers in North Carolina.

Other urology in New Bern

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →